Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Multidrug resistance in tumour cells: characterization of the multidrug resistant cell line K562-Lucena 1.

Anais da Academia Brasileira de Ciencias - 1 Mar 2001

Rumjanek V M, Trindade G S, Wagner-Souza K, de-Oliveira M C, Marques-Santos L F, Maia R C, Capella M A

Abstract excerpt

Multidrug resistance to chemotherapy is a major obstacle in the treatment of cancer patients. The best characterised mechanism responsible for multidrug resistance involves the expression of the MDR-1 gene product, P-glycoprotein. However, the resistance process is multifactorial. Studies of multidrug resistance mechanisms have relied on the analysis of cancer cell lines that have been selected and present...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antineoplastic Agents, Phytogenic
Share to ATP Binding Cassette Transporter, Subfamily B, Member 1

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to Drug Resistance, Multiple

Share to Drug Resistance, Neoplasm

Share to Gene Expression

Share to K562 Cells

Share to Leukemia, Erythroblastic, Acute

Share to Vincristine

Source

Identifiers

PMID: 11246270
DOI: 10.1590/s0001-37652001000100007

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Multidrug resistance in tumour cells: characterization of the multidrug resistant cell line K562-Lucena 1.PMID 11246270Read ↗

Characterization of a multidrug-resistant chronic myeloid leukemia cell line presenting multiple resistance mechanisms.Semantic proximity Read ↗

Multidrug resistance in chronic myeloid leukaemia: how much can we learn from MDR–CML cell lines?Semantic proximity Read ↗

Prediction of Broad Spectrum Resistance of Tumors towards Anticancer DrugsSemantic proximity Read ↗

[Resistance to chemotherapy: current progress].Semantic proximity Read ↗

CG5/Dx human breast cancer cell line: characterization of a new doxorubicin-resistant variant.Semantic proximity Read ↗

Characterization of a multidrug resistant human erythroleukemia cell line (K562) exhibiting spontaneous resistance to 1-beta-D-arabinofuranosylcytosine.Semantic proximity Read ↗

Dexrazoxane significantly impairs the induction of doxorubicin resistance in the human leukaemia line, K562.Semantic proximity Read ↗

[Multiple drug resistance--theoretical and clinical aspects].Semantic proximity Read ↗

Human leukemia K562 cell mutant (K562/OA200) selected for resistance to okadaic acid (protein phosphatase inhibitor) lacks protein kinase C-epsilon, exhibits multidrug resistance phenotype, and expresses drug pump P-glycoprotein.Semantic proximity Read ↗

Susceptibility of multidrug-resistant human leukemia cell lines to human interleukin 2-activated killer cells.Semantic proximity Read ↗

Multidrug resistance in oncology: diagnostic and therapeutic approachesSemantic proximity Read ↗

Multidrug resistance: clinical relevance in haematological malignancies.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.